LIXTE Biotechnology Holdings, Inc. Overview
Pro stress-test →LIXTE is a clinical-stage pharmaceutical company developing innovative cancer therapies using PP2A inhibition with LB-100. The company is focused on advancing a first-in-class PP2A inhibitor platform designed to enhance established chemotherapy and immunotherapy regimens, conducting multiple active clinical trials in solid tumors with significant unmet medical need.
Strategic Profile
Pro stress-test →LIXTE's scientific strategy is protected by a comprehensive patent portfolio, with management noting no known direct competitors targeting PP2A inhibition. Strategic actions in 2025, including the acquisition of Liora Technologies and a registered direct offering completed in December 2025, reflect an effort to broaden capabilities, with expansion of the ovarian clear cell carcinoma trial in December 2025 planned to double patient enrollment and present initial findings in 2026.
Competitive Landscape
Pro stress-test →LIXTE's first-in-class PP2A inhibitor platform has no known direct competitors in the PP2A inhibition space. The company positions itself as an enhancement to existing cancer therapies rather than a standalone treatment, differentiating from traditional oncology approaches.
Industry Context
LIXTE Biotechnology Holdings, Inc. operates in Clinical-stage oncology therapeutics.
Key facts
Founded: 2005 · Headquarters: East Setauket, US · Employees: N/A · Revenue: N/A · Market cap: N/A